Lunai Bioworks (LNAI) Debt Ratio (2011 - 2025)

Lunai Bioworks (LNAI) posted quarterly Debt Ratio of 0.19 for Q4 2025, up 25.69% quarter-over-quarter from 0.15 in Q3 2025.

Lunai Bioworks (LNAI) Debt Ratio (2011 - 2025) Analysis & Trends

Lunai Bioworks' Debt Ratio history runs 9 years deep, the most recent figure standing at 0.19 for Q4 2025.

In Q4 2025, Debt Ratio changed N/A year-over-year to 0.19; the TTM figure through Dec 2025 stood at 0.19 (changed N/A YoY), while the FY2025 annual figure was 0.44, changed N/A from the prior year.
Debt Ratio for Q4 2025 stood at 0.19, up from 0.15 in the prior quarter.
The five-year high for Debt Ratio was 0.44 in Q2 2025, with the low at 0.02 in Q2 2021.
The 3-year median for Debt Ratio is 0.06 (2022), against an average of 0.12.
The sharpest annual moves came in 2021 and 2022: Debt Ratio sank 44.59% in 2021, then soared 123.94% in 2022.
Lunai Bioworks' Debt Ratio stood at 0.03 in 2021, then jumped by 121.5% to 0.06 in 2022, then surged by 234.89% to 0.19 in 2025.
Business Quant data shows LNAI's Debt Ratio at 0.19 in Q4 2025, 0.15 in Q3 2025, and 0.44 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.05
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.26
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.47
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.03
10	Lunai Bioworks	6.87 Mn	3.72 Mn	20,942.00	-

Download Data